Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients
Based on our dosing simulations, the initial dosage of NIR/RIT was 300mg/100mg twice a day in critically ill patients with CrCL>45 mL/min; When CrCL in critically ill patients is between 15 and 45 mL/min, NIR/RIT is 150mg/100mg twice a day. The maintenance dose is adjusted according to CrCL and AUC of RIT, with the dosages varying between 75mg/100mg and 300mg/100mg.
Authors
- Yizhen Huang
- Ping Yang (ORCID: https://orcid.org/0000-0001-7960-6248)
- Rong Dong (ORCID: https://orcid.org/0000-0003-2372-9833)
- Xuben Yu (ORCID: https://orcid.org/0000-0003-1897-4519)
- Lu Li (ORCID: https://orcid.org/0000-0003-4573-8538)
- Ling Xiao (ORCID: https://orcid.org/0000-0003-0199-5137)
- Saiping Jiang (ORCID: https://orcid.org/0000-0001-7720-2725)
- Qiaoqiao Shentu
- Wenqiao Yu (ORCID: https://orcid.org/0000-0003-3940-2237)
- Na Chen
Institutions
- Nantong University (CN)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Jinhua Academy of Agricultural Sciences (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Dongyang People's Hospital (CN)
- Jinhua Central Hospital (CN)
- Yuxian People's Hospital (CN)
Publication Details
- Journal
- Infection and Drug Resistance
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/idr.s471918
- Citations
- 1
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- National Natural Science Foundation of China